VERONA PHARMA
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. The company creates therapies to address unmet medical requirements in the treatment of respiratory disorders. Verona Pharma was established in 2005 by Clive Page in London, England.
VERONA PHARMA
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2005-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.veronapharma.com
Total Employee:
51+
Status:
Active
Contact:
+44 20 7863 3300
Total Funding:
1.51 B USD
Technology used in webpage:
Domain Not Resolving IPv6 ReCAPTCHA ReCAPTCHA V2 UNPKG Akamai Hosted
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Current Advisors List
Board_member
2014-01-01
Board_member
Current Employees Featured
Clive Page Co-Founder @ Verona Pharma
Co-Founder
Kathleen Rickard Chief Medical Officer @ Verona Pharma
Chief Medical Officer
2019-01-01
David Zaccardelli President and Chief Executive Officer @ Verona Pharma
President and Chief Executive Officer
2020-02-01
Mark W. Hahn Chief Financial Officer @ Verona Pharma
Chief Financial Officer
2020-02-01
Anders Ullman Non Executive Director @ Verona Pharma
Non Executive Director
2013-05-01
Desiree Luthman Vice President, Regulatory Affairs @ Verona Pharma
Vice President, Regulatory Affairs
2017-01-01
Stock Details
Investors List
Oaktree Capital Management
Oaktree Capital Management investment in Post-IPO Debt - Verona Pharma
Ontario Municipal Employees Retirement System
Ontario Municipal Employees Retirement System investment in Post-IPO Debt - Verona Pharma
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Verona Pharma
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Verona Pharma
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Verona Pharma
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Verona Pharma
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Verona Pharma
Abingworth
Abingworth investment in Post-IPO Equity - Verona Pharma
David Ebsworth
David Ebsworth investment in Post-IPO Equity - Verona Pharma
Foresite Capital
Foresite Capital investment in Post-IPO Equity - Verona Pharma
Key Employee Changes
Date | New article |
---|---|
2020-02-03 | Verona Pharma appoint new CEO and CFO |
2020-01-07 | Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations |
Official Site Inspections
http://www.veronapharma.com Semrush global rank: 1.46 M Semrush visits lastest month: 17.06 K
- Host name: 192.0.66.210
- IP address: 192.0.66.210
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110

More informations about "Verona Pharma"
About Us | Verona Pharma
Verona Pharma is committed to improving the lives of patients with respiratory conditions through innovative prescription medicines. Learn about our vision to meet unmet medical needs, our agile approach, and leadership team.See details»
Verona Pharma - Crunchbase Company Profile
Contact Email info@veronapharma.com Phone Number +44 20 7863 3300 Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic …See details»
Contact Us - Verona Pharma
IR@veronapharma.com. Argot Partners. verona@argotpartners.com +1-212 600 1902. Media Relations. Ten Bridge Communications. tbcverona@tenbridgecommunications.com +1-781 …See details»
Verona Pharma Company Profile | Management and Employees …
Smith@veronapharma.com: Verona Pharma Top Competitors. Company Employees Revenue Top technologies; Synairgen. 17: $4.7 M: Topigen Pharmaceuticals. n/a: $4.5 M: KBP …See details»
Verona Pharma: Contact Details and Business Profile
Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and …See details»
Verona Pharma plc - AnnualReports.com
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.See details»
Verona Pharma
Nov 21, 2024 Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with …See details»
Verona Pharma Company Overview, Contact Details
May 9, 2024 Verona Pharma plc partners with The Ritedose Corporation. Verona Pharma is partnering with Ritedose, the largest sterile contract development manufacturing organization - …See details»
Mission, Vision & Core Values of Verona Pharma – CBM
Oct 2, 2024 Website: https://www.veronapharma.com; Mission: To discover and develop innovative drugs for the treatment of chronic respiratory diseases; Vision: ... A mission …See details»
Verona Pharma - Craft
Oct 29, 2024 Verona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, …See details»
Investor Relations | Verona Pharma
Nov 19, 2024 LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior …See details»
Verona Pharma Company Profile 2024: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Verona Pharma. Use the PitchBook Platform to explore the full profile.See details»
Verona Pharma Inc. | North Carolina Biotech Center
Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of respiratory diseases such as chronic …See details»
Verona Pharma - Overview, News & Similar companies - ZoomInfo
Oct 13, 2024 Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- …See details»
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides …
2 hours ago Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 un...See details»
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In ...
Sep 16, 2024 Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, …See details»
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides
2 hours ago Verona Pharma plc: Tel: +1-844-341-9901: Victoria Stewart, Senior Director of Investor Relations and Communications: IR@veronapharma.com: Argot PartnersSee details»
Company Leadership - Verona Pharma
Meet Verona Pharma's leadership team and Board of Directors, with extensive experience in global life sciences and a proven track record in the development and commercialization of …See details»
Verona Pharma Reports Approximately $36 Million in Q4 2024 Net …
2 hours ago Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Quiver AI Summary. Verona Pharma plc has announced its …See details»
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides …
2 hours ago About Verona Pharma. Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory …See details»